anti-HER2 ADC (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)

N/A

Report date: 2025/03/14 16:32:16

Base Information

Drug Nameanti-HER2 ADC (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A